Mizuiri Hirozumi, Yoshida Kazuhiro, Shimizu Katsuhiko, Tanabe Kazuaki, Taomoto Junya, Suzuki Takahisa, Wada Yoshiyuki, Hihara Jun
Dept. of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University.
Gan To Kagaku Ryoho. 2004 Nov;31(12):2043-6.
The patient was a 58-year-old man who suffered from non-resectable gastric cancer, staged intraoperatively for peritoneal dissemination and paraaorta lymph node metastasis at another hospital in December 2002. He was initially treated with TS-1 as an outpatient. However, he was readmitted on March 4, 2003 for hematuria, general fatigue, jaundice and dyspnea. He was diagnosed with gastric cancer duodenum invasion, obstructive jaundice and lymphangitis carcinomatosa, and began weekly TXL as second-line chemotherapy on March 26. TXL (70 mg/ m2) was infused once a week for 3 weeks followed by a 1-week interval as one cycle. One week after the first infusion therapy, the jaundice and dyspnea were greatly improved. CT scan showed the lymphangitis carcinomatosa had disappeared and paraaorta lymph node metastasis was reduced to 60% after one cycle of the treatment. The toxic events were leukopenia (grade 1) and alopecia (grade 1).
该患者为一名58岁男性，患有不可切除的胃癌，2002年12月在另一家医院接受手术时被分期为腹膜播散和腹主动脉旁淋巴结转移。他最初作为门诊患者接受替吉奥（TS-1）治疗。然而，他于2003年3月4日因血尿、全身乏力、黄疸和呼吸困难再次入院。他被诊断为胃癌侵犯十二指肠、梗阻性黄疸和癌性淋巴管炎，并于3月26日开始每周使用紫杉醇脂质体（TXL）作为二线化疗。TXL（70mg/m²）每周输注一次，共3周，随后间隔1周为一个周期。第一次输注治疗一周后，黄疸和呼吸困难得到明显改善。CT扫描显示，经过一个周期的治疗，癌性淋巴管炎消失，腹主动脉旁淋巴结转移减少至60%。毒性反应为1级白细胞减少和1级脱发。
